Relationship between proprotein convertase subtilisin/kexin type 9 (PCSK9) and thrombotic events in primary antiphospholipid syndrome. The multicenter ATHERO-APS study

Le résumé fourni par la source

Abstract Background The proprotein convertase subtilisin/kexin type 9 (PCSK9) is a novel cardiovascular risk factor. Levels of PCSK9 in thrombotic primary antiphospholipid syndrome (PAPS) have never been investigated. Methods Cross sectional comparison of baseline characteristics of 91 PAPS patients enrolled in the multicenter ATHERO-APS cohort study. PCSK9 levels were categorized into tertiles and the association with arterial and recurrent thrombosis were assessed by univariable and multivariable regression analysis. Results Median age was 51 years and 71.4% (n=65) were women. Overall, 33% (n=30) experienced an arterial event while 31% (n=28) had recurrent thrombotic events. Median PCSK9 levels were 1243 (1100–1650) pg/ml. Patients in the third PCSK9 tertile (>1458 pg/ml) showed a higher prevalence of dyslipidemia, lupus anticoagulant positivity and a history of previous arterial and recurrent thrombosis than patients in the first and second tertile. PCSK9 levels were higher in arterial than venous thrombosis (1502 vs. 1180 pg/ml, p=0.002), and in patients with recurrent vs isolated thrombosis (1680 vs. 1150 pg/m, p<0.001). High plasma PCSK9 levels were associated with a 4-fold increase risk for arterial events and with a 10-fold increase risk for recurrent thrombosis after adjustment for confounding factors. Conclusion These preliminary data suggest that in PAPS, PCSK9 levels are associated with arterial and recurrent thrombosis. Its role as a possible therapeutic target in PAPS needs further studies. Funding Acknowledgement Type of funding sources: None.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.